ICCVAM Biennial Report 2020-2021

FDA CDER pursues international harmonization of nonclinical recommendations for human pharmaceutical development through their engagement with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH brings together regulatory authorities and the pharmaceutical industry to discuss scientific and technical aspects of drug registration. ICH's mission is to achieve greater harmonization worldwide to ensure that safe, effective, and high-quality medicines are developed and registered in the most resource-efficient manner. These activities reduce repetition of studies and reduce and refine animal use in overall drug development. New guidances recently approved will continue to contribute to the 3Rs as will future guidances that are currently being developed or revised.

FDA solicited comment in October 2021 on a draft addendum to ICH guidance on carcinogenicity testing and published guidance aligned with ICH documents on evaluation of developmental and reproductive toxicity as discussed elsewhere in this report.